PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.\', \'Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.\', \'Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul 03080, Korea.\', \'Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul 03080, Korea.\', \'Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.\', \'Advanced Institute of Convergence Technology, Suwon 16229, Korea.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 545710.3390/ijms22115457
?:hasPublicationType
?:journal
  • International journal of molecular sciences
is ?:pmid of
?:pmid
?:pmid
  • 34064287
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.26
?:rankingScore_hIndex
  • 95
?:title
  • Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all